RxDoctor Payments Data

Michele Coulter, DO

Family Medicine · Tulsa, OKNPI 1780660522

Payments from drug & device makers

$5,006in general payments, 2019–2025

Across 342 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$683
  • GSK$394
  • Lilly USA, LLC$378
  • Corium, LLC$335
  • AstraZeneca$189
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,006 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$50,027
Medicare patients
188
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$66,411
OzempicSemaglutide57$59,972
MounjaroTirzepatide36$43,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$39,550
JanuviaSitagliptin Phosphate17$27,383
Breo ElliptaFluticasone/Vilanterol43$27,211
Rosuvastatin Calcium425$18,266
XareltoRivaroxaban12$18,200
Tresiba Flextouch U-100Insulin Degludec22$17,250
SavellaMilnacipran Hcl13$15,470
Spiriva HandihalerTiotropium Bromide14$9,504
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,386
Colestipol Hcl58$7,461
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,329
Raloxifene Hcl36$6,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$394$66,76179 claims
PfizerEliquis$683$66,41188 claims
Novo NordiskOzempic$116$59,97257 claims
Lilly USA, LLCMounjaro$378$43,79636 claims
MerckJanuvia$143$27,38317 claims
Johnson & JohnsonXarelto$31$18,20012 claims
AbbVieSavella, Synthroid$1,002$17,57046 claims
AstraZenecaBreztri Aerosphere, Symbicort$189$13,69226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →